Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Brooks Laboratories
Small Cap•293 Employees•IPO 2011
Current Price
₹62.63
-4.48 (-6.68%)Updated
Today's Range
₹61.00
₹65.88
₹62.63
52 Week Range
52W Low₹58.35
52W High₹164.02
₹62.63
Downside7.34%
Upside161.89%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹216.1 Cr
Market Cap
Total market value of companyP/E Ratio
10.00
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.42
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹7.32
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.10%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
-9.93%
ROCE
Return on Capital Employed. >15% is goodNet Margin
24.31%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
3.45%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
42.30%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
498.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.08
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹33.30
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
52.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Brooks Laboratories has demonstrated a remarkable turnaround in its latest quarter, reporting a substantial 498.00% increase in net profit, reaching 9.58 Cr. This strong quarterly performance indicates improving operational efficiency and a positive shift in profitability.
- •The company has shown robust top-line growth, with quarterly sales increasing by an impressive 42.30% to 25.5 Cr. This significant sales expansion suggests growing market demand and effective business strategies.
Weaknesses
5 points- •The company's stock trades at a very high P/E ratio of 153.00, significantly above industry averages. This valuation suggests the stock might be overvalued, posing a risk for potential investors seeking reasonable entry points.
- •Brooks Laboratories exhibits negative returns on capital employed (-9.93%), equity (-12.20%), and assets (-9.33%). This indicates the company is not effectively generating profits from its capital and assets, a major concern.
Opportunities
3 points- •Operating within the 'Pharmaceuticals' sector, Brooks Laboratories can capitalize on the robust and expanding global healthcare market. Increasing demand for medicines and healthcare services presents significant growth avenues for the company.
- •A notable increase in Domestic Institutional Investor (DII) holding from 0.00% to 10.38% over the past two years suggests growing institutional confidence in Brooks Laboratories' future prospects and potential for value creation.
Threats
4 points- •Brooks Laboratories faces intense competition from much larger and established players like Sun Pharma, Divi's Lab, and Cipla. These industry giants possess greater resources, market share, and R&D capabilities, posing a significant challenge.
- •The pharmaceutical industry is subject to stringent regulatory changes and compliance requirements. Any adverse policy shifts or increased scrutiny could significantly impact Brooks Laboratories' operations, costs, and market access.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹75.10 | +₹12.47 | +19.91% |
| R3 | ₹70.22 | +₹7.59 | +12.12% |
| R2 | ₹68.05 | +₹5.42 | +8.65% |
| R1 | ₹65.34 | +₹2.71 | +4.33% |
| PIVOT | ₹63.17 | 0.54 | 0.86% |
| CURRENT | ₹62.63 | - | - |
| S1 | ₹50.70 | -₹11.93 | -19.05% |
| S2 | ₹55.58 | -₹7.05 | -11.26% |
| S3 | ₹58.29 | -₹4.34 | -6.93% |
| S4 | ₹60.46 | -₹2.17 | -3.46% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+6.1% vs avg
1.10L
(02 Mar 2026)Delivery %+4.7% vs avg
54.8%
(02 Mar 2026)Avg Volume (20D)20-day average
1.03L
(03 Feb - 02 Mar)Avg Delivery %Trend ↓
50.1%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Vimta Labs Ltd
43.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Borosil Scientific Ltd |
 Divis Laboratories Ltd |
 |
 Suven Life Sciences Ltd |
 Tarsons Products Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
Brooks Laboratories Ltd
Brooks Laboratories Limited is a pharmaceutical company headquartered in Mumbai, India, that was established in 2002. Its primary business revolves around the manufacturing and sale of a diverse range of pharmaceutical products both domestically within India and in international markets.
The company's product portfolio encompasses a broad spectrum of dosage forms designed to cater to various medical needs. This includes liquid and dry powder injections, a specialized area focusing on carbapenem dry powder injectables, which are likely used to treat serious bacterial infections. They also produce tablets, oral suspensions (liquids taken orally), dry syrups (syrups in powder form requiring reconstitution), and ophthalmic and otic preparations (eye and ear drops respectively).
The wide variety of dosage forms suggests Brooks Laboratories caters to a broad range of therapeutic areas. While the specific therapeutic categories aren't explicitly stated, the inclusion of carbapenem injectables indicates a focus on treating severe bacterial infections, while the presence of oral and topical formulations (tablets, syrups, eye/ear drops) demonstrates a broader commitment to various treatment needs.
Brooks Laboratories' business model centers on the production and distribution of its pharmaceutical products. The company's international presence suggests a commitment to exporting its products, indicating a strategy focused on both the domestic Indian market and global markets. The success of this business likely depends on factors such as manufacturing efficiency, regulatory compliance in multiple markets, effective distribution networks, and the ongoing development of new and improved pharmaceutical formulations.
In summary, Brooks Laboratories Limited is a significant player in the Indian pharmaceutical industry, actively engaged in manufacturing and distributing a diverse range of pharmaceutical products across multiple dosage forms and likely therapeutic areas. Their international reach and focus on injectable medications, particularly carbapenems, indicate a dedication to addressing significant medical needs both within India and globally.
COMPANY FACTS - BROOKS
Registered Address
502, Kanakia Atrium-2,, Next to Hotel Courtyard Marriott,, Andheri Kurla Road,
Mumbai
MAHARASHTRA
IN
Tel: 912261933100
Website:https://www.brookslabs.net/
Investor Relations:http://www.brookslabs.net/financial-results-2.php
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 293
IPO Date: 02/09/2011
MANAGEMENT - BROOKS
Mr. Prashant Rathi
Chief Financial Officer
Ms. Krutika Rane
Compliance Officer, Company Secretary
Mr. Rajesh Mahajan
Executive Director
Mr. Bhushan Rana
Additional Executive Director
Mr. Jitendra Singh
Whole-Time Director
Dr. Durga Maity
Additional Director
Mr. Lalit Mahajan
Additional Non-Executive Independent Director
Mr. Manav Mahajan
Additional Non-Executive Independent Director
Ms. Usha Singh
Additional Non-Executive Independent Director
Investor Questions Answered
Brooks Laboratories Ltd (BROOKS) Stock FAQs
Get answers to the most common questions about Brooks Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Brooks Laboratories Ltd (BROOKS) is ₹62.63. Today, the stock has declined by ₹4.48 (6.68%), trading in a range of ₹61 to ₹65.88. The stock opened at ₹63.5 with a trading volume of 1,09,813 shares.
Brooks Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹216.1 crores, P/E ratio of 10.00, ROE of 6.10%, and ROCE of -9.93%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Brooks Laboratories Ltd (BROOKS) is ₹164.02, while the 52-week low is ₹58.35. Currently trading at ₹62.63, the stock is 4.1% away from its 52-week low and 61.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Brooks Laboratories Ltd stock at ₹62.63 depends on multiple factors. The stock is currently trading with a P/E ratio of 10.00 and P/B ratio of N/A. Today's performance shows a loss of 6.68%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Brooks Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹62.63, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Brooks Laboratories Ltd's key financial metrics include: P/E Ratio: 10.00, P/B Ratio: N/A, ROE: 6.10%, ROCE: -9.93%, Dividend Yield: 0.00%, EPS: ₹7.32, Book Value: ₹33.3, Debt-to-Equity: 0.08, and Current Ratio: N/A. The company's market cap stands at ₹216.1 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Brooks Laboratories Ltd stock opened at ₹63.5 and is currently trading at ₹62.63, showing a decline of ₹4.48 (6.68%). The intraday high is ₹65.88 and low is ₹61. The trading volume stands at 1,09,813 shares, indicating moderate market participation today.
Brooks Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 10.00, which means investors are willing to pay ₹10.00 for every ₹1 of earnings. With an EPS of ₹7.32, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Brooks Laboratories Ltd has a market capitalization of ₹216.1 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹62.63) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Brooks Laboratories Ltd has a book value of ₹33.3 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹62.63, which is 88.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Brooks Laboratories Ltd has a Return on Equity (ROE) of 6.10% and Return on Capital Employed (ROCE) of -9.93%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Brooks Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Brooks Laboratories Ltd has a debt-to-equity ratio of 0.08, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Brooks Laboratories Ltd has an Earnings Per Share (EPS) of ₹7.32, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹62.63 and P/E ratio of 10.00, investors are paying 10.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Brooks Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Brooks Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Brooks Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (10.00), ROE (6.10%), debt-to-equity (0.08), and growth rates. 2) Technical Analysis - Check 52-week range (₹58.35 - ₹164.02), moving averages, and chart patterns. 3) Valuation - Compare current price (₹62.63) with book value (₹33.30) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Brooks Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹62.63 is 526x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Brooks Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹58.35 - ₹164.02). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.08 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,09,813 shares. 5) Valuation Risk - P/E of 10.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Brooks Laboratories Ltd operates in the industry with key metrics: P/E ratio of 10.00, ROE of 6.10%, market cap of ₹216.1 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.08), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Brooks Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹62.63, with a 52-week range of ₹58.35 to ₹164.02. Based on fundamentals like P/E (10.00), ROE (6.10%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Brooks Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹62.63. 2) Fundamental Deterioration - Declining ROE (currently 6.10%), increasing debt (D/E: 0.08), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Brooks Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu